Insider · CIK 0001529196
Mark J Foley
Files at GKOS (GLAUKOS Corp), RVNC (Revance Therapeutics, Inc.). First filing Feb 28, 2025, latest Feb 28, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GKOS: GLAUKOS Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | GLAUKOS Corp | $2.5M 20,687 shares | -28% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | GKOS GLAUKOS Corp | AGrant or award Common Stock | +864 | $0.00 | $0 | 35,800 | Jun 2, 2025 |
| May 29, 2025 | GKOS GLAUKOS Corp | AGrant or award Common Stock | +2,108 | $0.00 | $0 | 57,221 | Jun 2, 2025 |
| May 29, 2025 | GKOS GLAUKOS Corp | AGrant or award Stock Option (Right to Buy)derivative | +3,149 | $0.00 | $0 | 3,149 | Jun 2, 2025 |
| Feb 26, 2025 | GKOS GLAUKOS Corp | MOption exercise Common Stock | +25,000 | $32.00 | $800k | 59,936 | Feb 28, 2025 |
| Feb 26, 2025 | GKOS GLAUKOS Corp | MOption exercise Common Stock | +15,000 | $24.69 | $370k | 74,936 | Feb 28, 2025 |
| Feb 26, 2025 | GKOS GLAUKOS Corp | SOpen-market sale Common Stock | -20,687 | $120.72 | $2.5M | 54,249 | Feb 28, 2025 |
| Feb 26, 2025 | GKOS GLAUKOS Corp | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 26, 2025 | GKOS GLAUKOS Corp | MOption exercise Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | UTender of shares Common Stock | -996,935 | $3.65 | $3.6M | 27,933 | Feb 6, 2025 |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | UTender of shares Common Stockindirect: See footnote | -110,913 | $3.65 | $405k | 0 | Feb 6, 2025 |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | DDisposition to issuer Common Stock | -27,933 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | AGrant or award Common Stock | +84,686 | $0.00 | $0 | 84,686 | Feb 6, 2025 |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | DDisposition to issuer Common Stock | -84,686 | - | - | 0 | Feb 6, 2025 |
| Feb 3, 2025 | RVNC Revance Therapeutics, Inc. | AGrant or award Common Stock | +27,933 | $0.00 | $0 | 1,024,868 | Feb 5, 2025 |
| Dec 31, 2024 | RVNC Revance Therapeutics, Inc. | AGrant or award Common Stock | +1,000 | $2.18 | $2,185 | 996,935 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.